U.S. Markets closed

What Analysts Recommend for CBAY and VKTX

Margaret Patrick
What Analysts Recommend for CBAY and VKTX

This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.